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Abstract
Background: The vascular endothelial growth factor (VEGF) family is central to cancer angiogenesis. However,
targeting VEGF as an anti-cancer therapeutic approach has shown success for some tumor types but not others.
Here we examine the expression of the expanded VEGF family in prostate cancer, including the Semaphorin (Sema)
family members that compete with VEGFs for Neuropilin binding and can themselves have pro- or anti-angiogenic
activity.
Results: First, we used multivariate statistical methods, including partial least squares and clustering, to examine
VEGF/Sema gene expression variability in previously published prostate cancer microarray datasets. We show that
unlike some cancers, such as kidney cancer, primary prostate cancer is characterized by both a down-regulation of
the pro-angiogenic members of the VEGF family and a down-regulation of anti-angiogenic members of the Sema
family. We found pro-lymphangiogenic signatures, including the genes encoding VEGFC and VEGFD, associated with
primary tumors that ultimately became aggressive. In contrast to primary prostate tumors, prostate cancer metastases
showed increased expression of key pro-angiogenic VEGF family members and further repression of anti-angiogenic
class III Sema family members. Given the lack of success of VEGF-targeting molecules so far in prostate cancer, this
suggests that the reduction in anti-angiogenic Sema signaling may potentiate VEGF signaling and even promote
resistance to VEGF-targeting therapies. Inhibition of the VEGF ‘accelerator’ may need to be accompanied by promotion
of the Sema ‘brake’ to block cancer angiogenesis. To leverage our mechanistic understanding, and to link multigene
expression changes to outcomes, we performed individualized computational simulations of competitive VEGF and
Sema receptor binding across many tumor samples. The simulations suggest that loss of Sema expression promotes
angiogenesis by lowering plexin signaling, not by potentiating VEGF signaling via relaxation of competition.
Conclusions: The combined analysis of bioinformatic data with computational modeling of ligand-receptor
interactions demonstrated that enhancement of angiogenesis in prostate cancer metastases may occur through two
different routes: elevation of VEGFA and reduction of class 3 Semaphorins. Therapeutic inhibition of angiogenesis in
metastatic prostate cancer should account for both of these routes.
Background
The vascular endothelial growth factor (VEGF) family
plays an important role in promoting tumor angiogenesis,
making it an attractive target in the development of cancer
therapies. Therapies targeting VEGF family proteins
have had success in several cancer types: bevacizumab
in colorectal [1], lung [2], brain [3], and kidney [4];
aflibercept in colorectal [5]; sorafenib in kidney and
liver; sunitinib in gastrointestinal stromal, kidney, and
pancreatic neuroendocrine; pazopanib for kidney and
soft tissue sarcoma (www.cancer.gov). However, over-
all survival in prostate cancer has not been improved
by bevacizumab despite evidence for the importance
of angiogenesis in this disease [6]. Bevacizumab and
aflibercept treatment improves progression-free survival
in patients with metastatic castration-resistant prostate
cancer (CRPC) but has no effect on overall survival [7, 8],
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a pattern also observed in anti-VEGF clinical trials in
breast [9] and ovarian [10] cancers. One possible reason
for the failure of clinical trials is a lack of understanding of
who will respond best to angiogenesis inhibitors. Better
predictive biomarkers will allow for patient selection so
that patients will only be treated with VEGF inhibitors if
their tumors are sensitive to those inhibitors.
Several difficulties need to be overcome in developing
predictive biomarkers for angiogenesis inhibitors. For
example, the protein interactions within the VEGF path-
way are complex: there are five genes (VEGFA, VEGFB,
VEGFC, VEGFD, and PlGF) encoding ligands that bind
with differing affinities to three receptor tyrosine kinases
(VEGFR1, VEGFR2, and VEGFR3) and two neuropilin co-
receptors (NRP1 and NRP2). The VEGF receptors can
form complexes with the neuropilin co-receptors, altering
both effective ligand affinities and downstream signaling
outcomes [11]. An additional family of proteins, the sema-
phorins, also bind to neuropilins and inhibit angiogenesis,
potentially through competition with VEGF for neuropilin
binding sites [12]. The semaphorins also induce their own
signaling by binding to members of the plexin family; thus
the semaphorin/plexin family can modulate angiogenesis
by (a) regulating VEGF signaling through modulation of
neuropilin availability, and (b) direct anti-angiogenic signal-
ing through plexins. This makes it necessary to consider all
of these families when studying VEGF signaling. We previ-
ously observed that the aggressive triple-negative form of
breast cancer is associated with simultaneous up-regulation
of VEGFA and down-regulation of several class 3 sema-
phorins [13], both of which would be expected to increase
angiogenesis. Significant variation in angiogenesis-related
genes within the triple-negative subtype is also observed
[13, 14]. In this study we will determine whether there are
any associations between VEGF/Sema gene expression and
prostate cancer prognostic factors.
Development of prostate cancer biomarkers has focused
on two key questions: (a) whether localized tumors will
become aggressive or remain indolent; and (b) treatment
selection for metastatic CRPC. For the former, gene
expression-based biomarkers have been developed to
predict whether a localized tumor will become aggressive.
These multicomponent biomarkers include Oncotype Dx
[15], Decipher [16], and others [17–21], and are often
used in conjunction with clinical disease markers such
as Gleason score and pathological stage. Predictive bio-
markers of treatment response to metastatic tumors that
have progressed beyond androgen deprivation therapy
have received less attention, but the molecular alterations
present in such tumors have been studied [22, 23].
Here we consider expression of VEGF and semaphorin
ligands and receptors across prostate cancer datasets. We
compare the expression of these genes to biomarkers of
indolent vs. aggressive primary tumors, and examine the
variability of expression of these genes in metastatic tumors
to propose biomarkers for selecting CRPC patients who
may be sensitive to drugs that inhibit angiogenesis. We also
apply a novel technique incorporating gene expression
variability into computational models of growth factor
pharmacodynamics, in order to predict the activation of
VEGF and Sema receptors across a population of pros-
tate cancer patients. Thus, we use molecular mechanism
as well as high-throughput data to improve prediction and
insight.
Methods
A flowchart of the overall procedure of this study is in
Additional file 1: Figure S1.
Data
The datasets used in this study (Additional file 1: Table S1),
were obtained from the TCGA website (http://cancergen-
ome.nih.gov/) or from the National Center for Biotechnol-
ogy Information (NCBI) Gene Expression Omnibus (GEO)
database (http://www.ncbi.nlm.nih.gov/geo/). The majority
of samples were from primary, untreated tumors, but some
datasets also included normal prostate tissue samples and
tumors that had metastasized from the prostate to various
locations in the body. The data for these samples were
included in the analysis, in separate groups distinct
from the primary tumors. Outcome data (time until
death) was not available, with the exception of some
TCGA samples. The TCGA and GSE21034 datasets in-
cluded biochemical recurrence (BCR) data, with times
indicating the duration between sample collection and
either BCR or BCR-free follow-up.
Comparison of prostate tissue types
To assess univariate differences in gene expression across
prostate tissue types (normal tissue, primary tumors, and
metastatic tumors), we performed t-tests for each gene with
multiple testing corrections. We also used partial least
squares discriminant analysis (PLS-DA) to find multivariate
patterns that differentiated the tissue types. Significance of
the PLS-DA models was determined from the classification
error after cross-validation. More details on these methods
can be found in the supplementary information.
We used three types of plots to show differences in
gene expression between tissue types (e.g. Fig. 1a-d
and Additional file 1: Figures S2-S5): density plots
show differences in the shapes of the distributions,
with the densities estimated using the R function dens-
ity with default kernel bandwidth; box plots show the
range of variation with statistics such as the median
and quartiles; and spike plots showed the individual
points to emphasize the range.
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Prognostic significance of PLS-DA biomarkers
Data for time to follow-up or biochemical recurrence
(BCR) was used to analyze survival of patients in dis-
tinct clinical or PLS-DA-derived groups. Log rank tests
were used to determine differences in the Kaplan-Meier
survival estimates between two classes, and Cox pro-
portional hazard models were used to compare the
effects of multiple continuous variables. More details
on survival analysis methods can be found in the sup-
plementary information (Additional file 1: Supplemen-
tary Methods).
Comparison of multiple tumor samples from single
patients
To assess the similarity of tumors from different meta-
static sites within the same patient, we scaled the
Fig. 1 Down-regulation of pro- and anti-angiogenic ligands in primary prostate tumors. a-d: VEGFA (a), PGF (b), and the receptor gene KDR (c) are
expressed at lower levels in prostate tumors than in normal prostate tissue in the TCGA dataset, as shown by the density plots (top), box plots (middle),
and spike plots (bottom). The co-receptor gene NRP1 (d) is expressed at slightly higher levels in tumors but has a similar overall distribution to normal
tissues. e-h: This contrasts with the TCGA renal cell carcinoma (kidney) dataset, where VEGFA (e), PGF (f), KDR (g), and NRP1 (h) are heavily up-regulated in
tumors. i VEGFA down-regulation in primary prostate cancer is observed across TCGA and microarray datasets, as is consistent down-regulation of class
three semaphorins. The number in the boxes indicates the two-tailed t-test p-value after multiple testing correction with the Benjamini-Hochberg proced-
ure. Only comparisons with corrected p-values less than 0.05 are displayed. The colors of the boxes indicate the magnitude of the t-statistic. The blue boxes
to the right of the rows indicate that a gene is significantly down-regulated in two or more datasets with no significant differences in other datasets
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metastatic tumor data in GSE38241 by subtracting the
mean expression of each gene in the normal samples.
Then we grouped the metastasis samples using K-means
clustering. Consensus clustering methods were applied to
determine the number of clusters. More details on cluster-
ing methods can be found in the supplementary informa-
tion (Additional file 1: Supplementary Methods).
Other gene expression-based biomarkers
We also analyzed other biomarkers (Additional file 1:
Table S2) using the same methodology just described.
Some were based on commercially available prostate
cancer diagnostics tests, such as Oncotype Dx and De-
cipher. In these cases, we used the genes in the diagnos-
tic test in PLS-DA models, rather than the proprietary
algorithms.
Simulation of VEGF/Sema binding
Binding of VEGF ligands and class 3 semaphorin ligands
to their receptors was modeled as a system of coupled
nonlinear ordinary differential equations. The model con-
sisted of a tumor compartment with two cell types, tumor
and endothelial, similar to models we have developed pre-
viously for the VEGF family [24]. Receptors were present
on both cell types and were able to bind the ligands present
in the interstitial space. Tumor cell protein production
rates were varied from nominal values using gene ex-
pression data from dataset GSE35988. More details on
the computational model can be found in Additional
file 2, with parameter values given in Additional file 2:
Tables S8-S12. Schematics of the reactions between
molecules and molecular complexes are shown in
Additional file 2: Figure S13, and general characteris-
tics of the model output are given in Additional file 2:
Figures S14 and S15.
Results
Primary prostate tumor VEGF/Sema alterations
To examine why prostate cancer is less susceptible to
VEGF inhibition, we first compared gene expression be-
tween primary prostate tumors and a cancer type that
typically does respond to VEGF inhibitors, renal cell
carcinoma [25]. Using the TCGA RNA-Seq dataset, we
found that while two key pro-angiogenic ligands, VEGFA
and PGF, were up-regulated in renal cell carcinoma, they
were down-regulated in primary prostate adenocarcinoma
(Fig. 1a, b for prostate, Fig. 1e, f for kidney). This could
indicate a lack of VEGF signaling for VEGF inhibitors to
target, making attempts at targeting the VEGF pathway in
prostate cancer futile. This pattern was observed for
other VEGF ligands: these genes were down-regulated
or unchanged in prostate cancer, whereas they were up-
regulated in renal cell carcinoma (Additional file 1:
Figures S2-S5). Similarly, the receptors VEGFR2 (KDR)
and NRP1 were decreased or relatively unchanged in
prostate primary tumors while they were up-regulated in
renal cell carcinoma (Fig. 1c, d for prostate, Fig. 1g, h
for kidney). This pattern was consistent across other
VEGF receptors (Additional file 1: Figures S2-S5). The
up-regulation of both ligands and receptors in renal cell
carcinoma clearly suggests the importance of VEGF sig-
naling in that case. However, the up- or down-regulation
of VEGF ligands and receptors in cancer types may not
fully explain the response to VEGF inhibitors in prostate
cancer. Subsets of tumors may have pro-angiogenic gene
expression despite the anti-angiogenic pattern in the tu-
mors as an overall group. Additionally, other pathways
that interact with the VEGF pathway may affect signaling.
We considered an additional set of genes that have been
demonstrated to affect VEGF signaling: the semaphorins
and their plexin receptors, bringing the total number of
VEGF/Sema-related genes under consideration to 39. We
expanded our comparison of normal prostate tissue and
primary prostate tumors to include multiple microarray
datasets in addition to the TCGA dataset (Additional file 1:
Table S1, note that only GSE6919, GSE21034, TCGA, and
GSE35988 contain both normal prostate tissue and primary
prostate tumors). For primary tumor versus normal tissue
comparisons, we measured differences in gene expression
using a two-tailed t-test with multiple testing correction
using the Benjamini-Hochberg procedure. We found that
in addition to VEGF ligands, many semaphorins were also
down-regulated in prostate cancer (Fig. 1i). In particular,
class 3 semaphorins, which have potential anti-angiogenic
effects due to their ability to compete with VEGF for neu-
ropilin binding, were down-regulated. Not all gene expres-
sion changes were consistent across all datasets; ones that
were significant (defined as q-value less than 0.05) in two
or more datasets were marked with blue or red boxes to
the right. The subset of genes consistently down-regulated
in primary tumors included three out of five VEGF ligands
(VEGFA,VEGFB, and VEGFC) and five out of seven class 3
semaphorins (SEMA3A, SEMA3B, SEMA3C, SEMA3D,
and SEMA3E). These results made the overall impact on
angiogenesis unclear as both pro-angiogenic VEGF signals
and anti-angiogenic semaphorin signals were reduced in
primary tumors.
A pro-lymphangiogenic gene expression signature is
associated with aggressive primary tumors
To assess whether some subsets of primary prostate tu-
mors may have differing potential benefits from VEGF
signaling inhibitors, we used partial least squares dis-
criminant analysis (PLS-DA), a multivariate algorithm
that allowed us to simultaneously consider both the
pattern of VEGF/Sema gene expression and effects on
an output variable. As an output, we used a binary
variable indicating whether biochemical recurrence
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(BCR) eventually occurred. Data for BCR/follow-up
times were available in the TCGA and GSE21034 datasets,
with 10 and 27 BCR events, respectively (Additional file 1:
Table S3). Since BCR-negative samples with short follow-
up times may eventually undergo recurrence, we used only
the ten and 27 BCR-negative samples with the longest
follow-up times in the TCGA and GSE21034 datasets,
respectively. These groups of indolent samples had follow-
up times greater than 3.3 years in the TCGA dataset and
greater than 5.2 years in the GSE21034 dataset. These
minimum indolent follow-up times were greater than all
but one of the times at which BCR occurred in the TCGA
dataset and all but three in the GSE21034 dataset. The
TCGA PLS-DA model was effective in differentiating
aggressive and indolent tumors, with a 92 ± 3 % training
accuracy (Fig. 2a). The GSE21034 PLS-DA model, on the
other hand, was less effective with only a 66 ± 1 % training
accuracy (Fig. 2b). This discrepancy in performance
between TCGA and GSE21034 datasets was seen for other
biomarkers meant to distinguish aggressive from indolent
tumors (Additional file 1: Figure S7). Notably, the VEGF/
Sema PLS-DA model (and PLS-DA models based on the
genes from other biomarkers) lost some of its predictive
ability when correcting for Gleason score, but still was
significantly prognostic (Additional file 1: Figure S8). ROC
curves from leave-one-out cross-validation barely deviated
from a 45-degree line (Additional file 1: Figure S6),
indicating that these models would likely be ineffective in
distinguishing aggressive and indolent tumors in other
datasets. ROC curves for PLS-DA models trained with the
478 genes of the “angiome”, a set of angiogenesis-related
genes [26], improved but were still fairly poor: the AUCs
for TCGA and GSE21034 were 0.72 and 0.66, respectively
(Additional file 1: Table S6). The 1,233 genes of the
extended angiome [26] also led to poor PLS-DA models,
with AUCs of 0.74 and 0.69 (Additional file 1: Table S7).
Nonetheless, the PLS-DA models provided gene expres-
sion signatures with potential prognostic significance:
when the PLS discriminant scores were used as predictive
variables in Kaplan-Meier survival analysis, aggressive and
indolent tumors had significantly different outcomes
(Fig. 2c, d).
Fig. 2 VEGF/Sema expression signatures predicting biochemical recurrence (BCR). a-b: PLS-DA scores/loadings plots for the TCGA (a) and
GSE21034 (b) datasets. The training accuracies and the discriminant line separating the two classes are displayed c-d: Survival curves show
prognostic significance of VEGF/Sema signatures in the TCGA (c) and GSE21034 (d) datasets. The p-values are from log rank tests of the
Kaplan-Meier survival estimators for each group
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The PLS-DA models also yielded information regard-
ing patterns of VEGF/Sema expression associated with
aggressive prostate tumors. The gene-specific loadings
vectors (arrows in Fig. 2a, b) are the projections of each
gene onto the latent variable space, and show the extent
to which different genes contribute to the variability in
the response variable. The loadings revealed that the
association of VEGF/Sema genes with aggressiveness
was different between the two datasets. For the TCGA
dataset, aggressive tumors were associated with high ex-
pression of FIGF (VEGFD), NRP2, PLXNA1, PLXNB1,
PLXNB3, and SEMA5B and low expression of PLXNB2
and SEMA4D. The first two of these genes, FIGF (VEGFD)
and NRP2, mediate pro-lymphangiogenesis signals. The
process of lymphangiogenesis may provide tumors with a
route by which to escape their tissue of origin into the
bloodstream [27]. In the GSE21034 model, high expression
of VEGFC, KDR, and NRP1 and low expression of VEGFA
and SEMA4B were associated with aggressive tumors.
Although this signature was different from the one found
in the TCGA dataset, the high expression of VEGFC also
suggested a potential for lymphangiogenic activity in ag-
gressive primary tumors.
Metastatic prostate tumors are associated with a
pro-angiogenic signature
While primary tumors are often treated with surgery and
radiation, targeted therapeutics such as VEGF inhibitors are
used more often in metastatic disease. Therefore, we next
considered VEGF/Sema gene expression in datasets with
metastatic tumors (Additional file 1: Table S1, note that
only GSE6919, GSE21034, GSE32269, and GSE35988 con-
tain both primary and metastatic tumors, while only GSE69
19, GSE21034, GSE38241, and GSE35988 contain both
normal prostate tissue and metastatic tumors). In contrast
to the reduced expression of VEGF ligands in primary tu-
mors, metastatic tumors tended to have higher expression
of the major pro-angiogenic ligand,VEGFA (Fig. 3a, b). This
ligand was up-regulated in metastases relative to primary
tumors and normal tumors in the GSE6919, GSE35988,
and GSE38241 datasets, but was actually down-regulated in
GSE21034 and GSE32269. Notably, metastatic samples in
the three datasets with up-regulated VEGFA were all
obtained from warm autopsy programs where samples were
processed rapidly upon the death of the patient. Metastatic
samples in GSE32269 were from bone marrow biopsies of
live patients, and no details were given regarding how
metastatic samples were obtained in the GSE21034 dataset.
The class 3 semaphorins were down-regulated in metasta-
ses relative to normal prostate tissue (Fig. 3b), suggesting
that the loss of semaphorin expression in primary prostate
tumors was maintained upon metastasis. SEMA3C was
further down-regulated relative to primary tumors as well.
Other expression alterations recurrent across datasets
included up-regulation of NRP1, PLXNA1, and PLXNA3
relative to both normal tissue and primary tumors. These
three genes participate in class 3 semaphorin signaling,
while only NRP1 participates in VEGF signaling. KDR and
NRP2 were recurrently down-regulated in metastases rela-
tive to normal tissue but not relative to primary tumors.
We used PLS-DA to show that the VEGF/Sema gene
expression alterations present in metastatic prostate tu-
mors differed significantly from both normal tissue and
primary tumors. PLS-DA models comparing metastases
with primary tumors in the GSE35988 dataset and with
normal tissue in the GSE38241 dataset led to large
separation between the PLS scores of the two classes
(Fig. 3c, d and Additional file 1: Figure S9). The leave-
one-out cross-validation accuracy was 100 % for both
of these comparisons.
VEGF/Sema alterations are consistent across multiple
metastases within individual patients
The metastasis samples in the GSE38241 dataset included
three to four metastases per patient from five different
patients, providing the opportunity to analyze VEGF/Sema
gene expression in both inter- and intra-patient contexts.
We observed a high degree of consistency between metas-
tases from the same patient, with VEGFA consistently up-
regulated and several class 3 semaphorins, KDR, and NRP2
consistently down-regulated (Fig. 4a; the numbers 16, 17,
21, 22, and 30 on the x-axis correspond to different pa-
tients). Some genes that were not significantly altered
when comparing all metastases to normal samples did
show patient-specific alterations: VEGFC and SEMA6A
were up-regulated in some metastases and down-regulated
in others. SEMA6A was consistent within patients, while
VEGFC was not.
To assess the overall consistency of metastases from indi-
vidual patients, we performed consensus K-means cluster-
ing of the metastatic samples and compared the clusters to
the patients of origin. Repeating the clustering on random
subsets of the data yielded a consensus matrix with clear
separations of the groups when the number of clusters was
five (Fig. 4b, c and Additional file 1: Figure S10). This did
not perfectly separate the patients, but there was a signifi-
cant association between clusters and patients (χ2 test p =
0.001). We also found that if we expanded our set of genes
beyond VEGF/Sema to include other ligands and recep-
tors important in angiogenesis (specifically, the EGF/ErbB
family, HGF/Met, the Ang/Tie family, the PDGF/PDGFR
family, and the IGF/IGFR family), we obtained consensus
K-means clusters that resulted in perfect separation of the
patients into clusters (Fig. 4d, e). This supports the
hypothesis that, although signaling pathways that contrib-
ute to angiogenesis may vary from patient to patient, the
multiple metastases that can arise from a single prostate
tumor would likely all respond (or not respond) to the
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Fig. 3 (See legend on next page.)
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same or similar therapies. That this broader set of recep-
tor tyrosine kinases and their associated ligands improves
patient stratification is consistent with the need to under-
stand a broader angiome beyond VEGF.
Computational modeling of the VEGF/Sema pathway
stratifies patients
To further analyze the contributions of gene expression
changes to angiogenesis-related signaling, we developed a
computational model consisting of ordinary differential
equations (ODEs) describing the ligand-receptor binding
kinetics of the five VEGF ligands and seven class 3
Semaphorins. A detailed model is essential, given the high
inter-individual variability in gene expression, and given
that predicting the outcome on signaling of simultaneous
changes in expression of multiple genes encoding compet-
ing ligands and receptors becomes difficult. For a more de-
tailed description of the model development, see Methods
and Additional file 2. A key component of the model is that
it incorporates both tumor cells and tumor endothelial
cells, and these cells can express both the ligands and
receptors of the VEGF and Sema pathways. Instead of using
an ‘average’ model, the tumor cell ligand and receptor pro-
duction rates were varied based on the gene expression
data in the GSE35988 dataset, which included normal pros-
tate, primary prostate tumors, and metastatic tumors. This
enabled us to run many simulations – one for each individ-
ual – and to predict the amounts of VEGF and Semaphorin
signaling complexes in a patient-specific manner.
The results of simulating many individuals with tumors
were divided into groups (benign, localized, metastatic) and
the distribution of predicted signaling outputs across the
population are calculated. Binding of the two major iso-
forms of VEGFA (VEGF165 and VEGF121) to VEGFR-2
and VEGFR-1 on endothelial cells was lowest in primary
(localized) tumors, whereas the collective binding of the
class 3 Semaphorins to endothelial plexins decreased in
primary tumors relative to normal tissue and decreased
further in metastatic tumors (Fig. 5a). The receptor bind-
ing trends closely followed ligand expression levels, with
VEGFA expression being the predominant factor driving
VEGFR-1/2 binding, while the total Sema3 expression
accounted for most of the variation in Sema3-NRP-PlxnA
binding (Fig. 5b). The receptor binding profiles on tumor
cells (Additional file 1: Figure S12) were similar to those
on endothelial cells. These results indicated that primary
tumors are associated with both pro-angiogenic (decreased
Sema3-NRP-PlxnA binding) and anti-angiogenic (de-
creased VEGFR-2 binding) alterations, making it diffi-
cult to predict whether primary tumors would benefit
from therapies that inhibit VEGF signaling. On the other
hand, the alterations in metastatic tumors were all pro-
angiogenic: VEGFR-2 binding was higher and Sema3-NRP-
PlxnA binding was lower. The range of VEGFR-2 binding
was highest in metastatic samples, going beyond both the
low and high ends of the range of normal samples. This
suggested an important role for patient selection in the use
of anti-angiogenic therapies, as only the patients with high
baseline VEGFR-2 signaling would be expected to respond.
Aside from anti-angiogenic signaling initiated by Sema3
binding to neuropilins and plexins, Sema3s also may in-
hibit angiogenesis by competitively displacing VEGF from
neuropilins. In our model, we found only a weak competi-
tive effect: the least squares fits for the non binding ligand-
receptor pairs (VEGFA effects on Sema3-NRP-PlxnA and
Sema3 effects on VEGFA-VEGFR-2 in Fig. 5b) had slight
negative slopes, but the least squares models explained a
very small proportion of the overall variance. This was due
to the fact that the amount of NRP1 and NRP2 present in
ligand-containing signaling complexes was low relative to
the total amount of neuropilins present on endothelial
cells. If the amount of endothelial NRP1 and/or NRP2 were
lower or the ligand secretion rates were higher, competition
would be expected to have more impact. Thus, although
direct VEGF-Sema competition for neuropilin is included
in the model, the quantitative impact of the competition is
predicted to be small.
Our simulation results suggest that determining patients
with sensitivity to anti-angiogenic therapies would require
biomarkers consisting of multiple predictor variables. Each
individual tumor has a different predicted level of VEGFA-
VEGFR-2 and low Sema3-NRP-PlxnA activity (Fig. 5c).
The red and blue gradients, and the arrows on the axes,
indicate direction of increasing pro-angiogenic signal-
ing for VEGFR2 (accelerator ‘ON’) and PlxnA1 (brake
‘OFF’), respectively. Metastatic samples predominantly
have high simulated VEGFA-VEGFR-2 and low Sema3-
NRP-PlxnA (lower right quadrant of Fig. 5c: accelerator
(See figure on previous page.)
Fig. 3 Pro-angiogenic VEGF/Sema gene expression in prostate cancer metastasis. a-b: A greater number of VEGF/Sema genes have recurrent
expression alterations when comparing metastases to normal samples (b) than to primary tumor samples (a). The p-values are displayed according
to the same criteria as in Fig. 1, and red and blue boxes on the right hand sides of panels a and b indicate recurrent up- and down-regulation,
respectively. c-d: PLS-DA scores plots show separation of metastases and primary tumors in GSE35988 (c) and of metastases and normal tissues in
GSE38241 (d). Each dot represents a sample with colors as indicated. Arrows correspond to gene loadings in the PLS-DA models, with the names
of the genes displayed in the vicinity of the arrowhead. Only the genes with the largest magnitude loadings vectors are displayed. Accuracy refers
to the accuracy of the LOOCV predictions; AUC refers to the area under the curve of the LOOCV ROC curve. In both cases, values of one indicate
perfect prediction










































































































VEGF/Sema Genes Expanded Set of Angiogenic Genes 
E 
D 
Co-Clustering Frequency Co-Clustering Frequency 
Fig. 4 (See legend on next page.)
Bender and Mac Gabhann BMC Systems Biology  (2015) 9:55 Page 9 of 14
‘ON’, brake ‘OFF’), and would be expected to benefit
the most from VEGF-targeting therapies. However, this is
not true of all metastatic tumors; a minority of patients
with high VEGFA-VEGFR-2 also have high Sema3-NRP-
PlxnA, possibly negating any clinical benefit of an anti-
VEGFA agent. That combination is also predicted to be the
most common for the benign tissues (Fig. 5c, green
symbols). There are also a subset of metastatic tumors pre-
dicted to have low VEGFA-VEGFR2 signaling. This hetero-
geneity amongst the metastatic tumors reinforces the need
to bring an individualized understanding to therapeutic se-
lection. For those with localized disease (Fig. 5c, orange
symbols) the characteristic signaling state is low VEGFA-
VEGFR2 and high Sema-Plexin (upper left quadrant of
Fig. 5c: accelerator ‘OFF’, brake ‘ON’), correlating with low
angiogenesis potential and no metastases. Further analysis
of this model and availability of both gene expression and
clinical anti-VEGF outcome data will allow us to develop
simulation-based biomarkers.
Discussion
As with many types of cancer, angiogenesis may enable
prostate cancer growth and progression. Tumor vessels
tend to be more irregular than normal prostate vessels
[6, 28], and higher microvessel density is associated with
higher tumor stage [29, 30]. Some studies have reported
a reduction in tumor microvessel density relative to nor-
mal prostate tissue, but even in these studies it is noted
that ’hotspots” exist i.e. regions with locally high micro-
vessel densities [28]. Prostate tumors are known to have
intra-tumoral heterogeneity [31, 32], raising the possi-
bility that these hotspots correspond to regions with a
pro-angiogenic genomic signature. Multiple molecular
regulators of angiogenesis could be responsible for the
tumor-associated changes in the microvasculature. The
predominant pro-angiogenic factor, VEGFA, is elevated
in the plasma of patients with metastatic prostate can-
cer, but not in patients with localized primary prostate
tumors [33–37] (Additional file 1: Table S4). This does
not rule out a role for VEGFA in primary tumors, as
immunohistochemistry has revealed increased VEGFA in
primary tumors relative to benign prostate tissue, and in
castration-resistant tumors relative to hormone-naïve [38].
Our analysis of previously published gene expression data
in this study revealed increases in VEGFA expression only
in metastatic tumor samples; VEGFA expression in pri-
mary tumors was actually decreased. Despite elevations in
VEGFA in metastatic disease, most VEGF inhibitors have
failed clinical trials in metastatic CRPC [7, 8, 39, 40]
(Additional file 1: Table S5). One compound that has
shown some promise in phase II trials, cabozantinib,
also targets the Met receptor [41]. The lack of success
of VEGF inhibitors suggests that other angiogenesis
modulators may be involved. Therefore, we performed
an analysis of VEGF-related genes and a family of potential
modulators, the semaphorins, across stages of prostate can-
cer to gain a system-wide perspective on VEGF activity in
this disease. Our methodology could be widened in the
future to include additional relevant RTK families, includ-
ing those most relevant to angiogenesis (Fig. 4e).
An active area of research in prostate cancer molecular
biomarkers is predicting whether a primary tumor will
eventually become aggressive or if it will remain indolent
as indolent prostate cancers can often be left untreated
and monitored. We found that a multivariate VEGF/Sema
signature was associated with aggressive tumors. We used
PLS-DA for distinguishing between aggressive and indo-
lent tumors, as well as different tissue types, as it provided
both effective classification and information about the cor-
relation structure within the gene expression data. This
allowed for interpretation of the expected joint effects of
expression variation on VEGF signaling activity. We ex-
pected the performance of this approach to be comparable
to other multivariate methods used for similar purposes,
including linear discriminant analysis [18], random forests
[16], and decision trees [19]. Our VEGF/Sema PLS-DA
biomarkers had similar prognostic capabilities to PLS-DA
biomarkers based on the genes from other prostate cancer
prognostic indicators available and in development for clin-
ical use. We used PLS-DA, as opposed to the algorithm
actually used in the prognostic indicators, because the
algorithms and parameters used in these indicators were
proprietary. The VEGF/Sema signature of aggressiveness
that we found contained several genes that promote lym-
phangiogenesis, including FIGF (VEGFD), NRP2,VEGFC,
and KDR. This fits with previous research that suggests
(See figure on previous page.)
Fig. 4 Intra-patient variability of metastases is low relative to inter-patient variability. a Many genes have consistent alterations in metastatic
samples from the same patient while variable expression patterns between patients are more common. Blue box plots indicate the range of
expression in the 21 normal samples, with the upper and lower ends of the boxes corresponding to the third and first quartiles of the data,
respectively. The numbers along the x-axis indicate to which patient the dots above correspond. b Consensus K-means clustering of GSE38241
metastases according to VEGF/Sema expression shows a consistent co-clustering pattern for 5 clusters. Dark blue indicates a high frequency of
co-clustering between consensus runs, while white indicates no co-clustering. Colors at the top and left indicate the patient from which each
metastatic sample was taken. c Heatmap of gene expression across 18 GSE38241 metastases. The mean expression of each gene in the normal
prostate tissue samples is subtracted from the expression of each gene in the metastases so that the heatmap shows up/downregulation relative
to normal. Only the most variable of the VEGF/Sema genes are displayed. Dashed lines separate clusters, and colors at the top correspond to
patients as in b. d-e: As for b and c, but with the set of 85 angiogenesis-related genes
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lymphangiogenesis plays a role in allowing primary tu-
mors to escape their tissue of origin via the lymphatic
vessels [27, 42, 43]. Inhibiting one or more of these
genes could be an effective therapeutic mechanism in
patients whose tumors are predicted to be aggressive,
possibly as a neoadjuvant therapy prior to radical
prostatectomy.
Most approaches to targeting VEGF-dependent can-
cer angiogenesis have relied on inhibiting VEGF or VE
GFR2. This focus on blocking the accelerator of tumor







































































































































































































































Fig. 5 Simulated VEGF/Sema ligand-receptor binding on endothelial cells. a VEGFR2 (left), VEGFR1 (middle), and Sema3-NRP1 (right) binding in
benign prostate (n = 12), primary tumors (n = 49) and metastatic tumors (n = 27) in the GSE35988 dataset. The p-values are marked as follows: a
single * indicates p < 0.05, a double ** indicates p < 0.01, and a triple *** indicates p < 0.001. b VEGF secretion and total Sema3 secretion most
strongly affect their respective ligand-receptor complexes although weak competitive effects are observed. Lines represent least squares fits of
the log-transformed simulated receptor binding data to the gene expression data. R2 values represent the proportion of variance explained by
the least squares fit. c Scatter plots of simulated VEGFA-VEGFR2 and Sema3-NRP-PlxnA across tissue types show that only fraction of the metastatic
samples fall into the expected anti-VEGFA responsive region, i.e. high VEGFA-VEGFR2 signaling and low Sema3-NRP-PlxnA signaling. Gradients correlate
with expected favorability for angiogenesis: darker red for higher VEGFA-VEGFR2 and darker blue for lower Sema3-NRP-PlxnA. Colors indicate tissue
type: Benign (green); Localized (orange); Metastasis (gray)
Bender and Mac Gabhann BMC Systems Biology  (2015) 9:55 Page 11 of 14
angiogenesis may have overlooked a key aspect of tumor
angiogenesis – the endogenous brakes provided by the
Semaphorins. Analysis of metastatic tumor gene expres-
sion suggested several possible reasons for the failure of
anti-angiogenic therapies in prostate cancer. As noted
above, VEGFA expression was consistently elevated in
metastases relative to normal samples, but treatment of
metastatic prostate cancer with VEGF inhibitors typic-
ally fails. Reductions in class 3 semaphorins were ob-
served, which could enhance VEGF signaling by making
more NRP1 available; lower Sema3 levels could also en-
hance angiogenesis by removing inhibitory signals me-
diated by plexins (i.e. the brakes on tumor angiogenesis
are removed). Our simulation data provide mechanistic
insight that supports this latter case: Sema3s did not ap-
pear to alter the availability of NRP1 to VEGF, but the
formation of anti-angiogenic Sema3-Plexin complexes
was decreased in metastases. Thus one possible mech-
anism of resistance to VEGF inhibitors is reduced anti-
angiogenic Sema3 signaling. With the repression of
anti-angiogenic Sema signaling, blocking the accelerator
may be insufficient to halt the runaway tumor vascula-
ture; thus treatment might best be achieved, or aug-
mented, by restoring or replacing the endogenous
brakes on tumor angiogenesis.
We observed high correlation among the various metas-
tases from each individual (Fig. 4). These multiple metas-
tases arising from a single primary tumor may then
respond similarly to particular therapies. Also, given
recent findings of heterogeneity in primary tumors, it may
suggest that either (a) metastases come from a selected
subset of the primary tumor or (b) environments receiving
and nurturing metastases may cause the metastatic tumor
cells to converge. The gene expression clustering analysis
in this study also presented other possible resistance
mechanisms that we did not simulate. For example,
SEMA6A was up-regulated in metastases from two
patients and down-regulated in three. It has roles in
angiogenesis, potentially through an interaction with
VEGFR2 [44].
To move beyond the ‘average patient’ that is typically
simulated by molecularly-detailed mechanistic computa-
tional models, we have integrated mechanistic simula-
tions with high-throughput data to create a population
of tumor models that can simulate variability in receptor
activation and response to treatment. Our simulation
results suggest that determining patients with sensitivity to
anti-angiogenic therapies would require biomarkers con-
sisting of multiple predictor variables. This is one of the
most important considerations for this type of approach.
Linear approaches such as PLS-DA are ultimately limited
to identifying linear combinations of effects within the
gene expression data. By adding the mechanism-based,
quantitative, nonlinear protein-interaction network, we
can generate latent variables that integrate both gene
expression and mechanistic information. These predicted
mechanistic latent variables may then be more predictive
of the angiogenesis potential of the tumor and of the out-
come of therapeutic inhibition.
Simulations of the kind presented here can be ex-
panded to incorporate additional proteins and multiple
tissue compartments to model drug pharmacokinetics
and pharmacodynamics. This will be useful for develop-
ing patient-specific models capable of identifying the
most appropriate molecular therapies. Therapies could
include VEGF-targeting agents such as bevacizumab as
well as drugs that target neuropilin, either by blocking
ligand binding to neuropilin or by blocking the coupling
of neuropilin to other receptors. Inclusion of semaphor-
ins in these models allows us to analyze whether
neuropilin-targeting therapies could inadvertently have a
pro-angiogenic effect due to reduced semaphorin signal-
ing. Additional semaphorins (classes 4, 5, 6, and 7) could
be added as data for the kinetics becomes available. Fur-
ther development of the model could also address sev-
eral of the limitations of the current model. Proteolytic
processing is known to alter the receptor binding and
therefore the activity of VEGFC, VEGFD, and several of
the class 3 Semaphorins. We neglected these effects here
due to a lack of data describing the relative amounts of
processed and unprocessed forms in tumors. Addition-
ally, we have assumed that competition of VEGF and
class 3 Semaphorins occurs due to the inability of both
to occupy neuropilin receptors simultaneously. Further
validation against published in vitro data may allow us to
refine this assumption for specific VEGF and Semaphorin
ligands; there is evidence that certain ligands (and proteo-
lytically processed forms) are more or less able to sterically
inhibit the binding of other ligands to neuropilin.
Several limitations of gene expression data may affect
the conclusions of this study. Prostate tumors are typic-
ally multifocal and heterogeneous [23, 45], creating the
possibility of gene expression data for a patient that does
not reflect the clone that actually gives rise to aggressive
disease. This is a possible explanation for the difference
between the TCGA and GSE21034 datasets in the
VEGF/Sema signatures found in this study to distinguish
aggressive and indolent tumors. The lack of stability of
mRNA leads to further issues with the measurement of
mRNA expression. If appropriate protocols are not
followed, degradation of mRNA can lead to inaccuracies
in measurements. This is another possible explanation
for the discrepancy between the TCGA and GSE21034
aggressiveness predictors, as well as for the varying
changes in gene expression between metastatic samples.
The expression of VEGFA was up-regulated in metasta-
sis samples in GSE6919, GSE35988, and GSE38241, but
not in GSE32269 or GSE21034. The three datasets with
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VEGFA up-regulation were all obtained from rapid
autopsy programs of prostate cancer patients. Metastatic
samples in GSE32269 were obtained from bone marrow
biopsies, and the sampling protocol for GSE21034 was
not specified.
Additionally, gene expression levels are not always repre-
sentative of the level of the corresponding protein. Instead
of equating gene expression to protein levels, we assumed
that protein secretion rates were proportional to gene
expression in our patient-specific simulations. This is a
useful first approximation; further analysis could include
miRNA data and other regulatory factors that would be
expected to influence the rate of translation of a transcript
to a protein. A final limitation is the small size of metastasis
datasets. Metastatic samples are of particular interest be-
cause metastases give prostate cancer its lethality and here
we show that they may have increased VEGF signaling
activity. A larger rapid autopsy dataset would allow expan-
sion of limited analysis performed here.
Conclusions
Our analysis of gene expression data across normal
prostate, primary prostate tissue, and metastatic pros-
tate tumors revealed that while class 3 Semaphorin ex-
pression was reduced in both primary and metastatic
tumors, VEGFA expression was elevated only in meta-
static tumors. Within primary tumors, distinct clusters
based on VEGF/Sema expression were not observed, but a
pro-lymphangiogenic signature was associated with the
likelihood of a primary tumor eventually becoming ag-
gressive. Within metastatic tumors, alterations in VEGF/
Sema expression tended to vary between patients but not
between multiple metastases within a single patient.
We incorporated gene expression data into a mathem-
atical model of the ligand-receptor interactions among
all VEGF and class 3 Semaphorin ligands and their cor-
responding receptors. This was done by varying protein
production rates based on the level of expression of the
corresponding gene. At physiological ligand concentra-
tions, no competition between VEGF and Semaphorins
for Neuropilin binding was observed; instead, the level of
VEGF and Semaphorin signaling complexes were inde-
pendent, with some metastatic tumors exhibiting elevated
VEGFA receptor binding, others exhibiting reduced Sema-
phorin receptor binding, and some exhibiting both. The
therapeutic implications of this are that some patients
may require only an anti-VEGF drug to inhibit angiogen-
esis, others may require only augmentation of class 3
Semaphorin signaling, while others may require both. The
model also predicted that targeting Neuropilins might be
problematic due to reduction in anti-angiogenesis signaling
of Plexins confounding the reduction in pro-angiogenesis
signaling of VEGFRs.
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